TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4062396

Group type: EXPERIMENTAL
Intervention: Empirical antibiotic therapy (trimethoprim-sulfamethoxazole and erythromycin)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Immediate open lung biopsy
Number of subjects: 22
Study: 30244671

Group type: EXPERIMENTAL
Intervention: Inflammation factor score
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: High carotenoids and low interleukin-18 factor
Number of subjects: 290
Study: 27729174

Group type: EXPERIMENTAL
Intervention: Vaccine stored at elevated temperatures (25 °C for up to six months or 30 °C for three months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cold-chain stored vaccine (2–8 °C)
Number of subjects: 0
Study: 24114367

Group type: EXPERIMENTAL
Intervention: Preoperative education
Number of subjects: 74
Study: 22395923

Group type: EXPERIMENTAL
Intervention: Supported self-management intervention for COPD with ongoing support for 12 months.
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Successful self-management (42% of intervention group classified as successful self managers).
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Health-related quality of life measures (secondary outcome).
Number of subjects: 464
Study: 20445161

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 448

Group type: COMPARATOR
Intervention: Observation (no further treatment)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Optimal surgical staging
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Nonoptimal surgical staging
Number of subjects: 448
Study: 18041606

Group type: EXPERIMENTAL
Intervention: Peppermint aroma
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ylang-ylang aroma
Number of subjects: 144

Group type: COMPARATOR
Intervention: No aroma control
Number of subjects: 144
Study: 16048260

Group type: EXPERIMENTAL
Intervention: NEPP (1 dwell amino acids, 1 dwell icodextrin, and two dwells bicarbonate/lactate-buffered glucose-based solution)
Number of subjects: 63

Group type: COMPARATOR
Intervention: SPD (standard PD regimen; 4 dwells glucose-/lactate-based)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: NEPP
Number of subjects: 63

Group type: COMPARATOR
Intervention: SPD
Number of subjects: 63
Study: 12443582

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control
Number of subjects: 224
Study: 10500056

Group type: EXPERIMENTAL
Intervention: Infliximab (10 mg/kg every 8 weeks)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 8744663

Group type: EXPERIMENTAL
Intervention: Intravenous nalbuphine infusion (15 micrograms/kg/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (nalbuphine and saline)
Number of subjects: 60
Study: 1834049

Group type: EXPERIMENTAL
Intervention: Nafarelin (400 micrograms daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Danazol (600 mg daily)
Number of subjects: 49
Study: 7074641

Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by six courses of MOPP (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 177
Study: 30117359

Group type: EXPERIMENTAL
Intervention: Timed Up and Go (TUG) test
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Gait test utilizing OptoGait system
Number of subjects: 51
Study: 28917715

Group type: EXPERIMENTAL
Intervention: Attentional bias modification procedure
Number of subjects: 0
Study: 27435799

Group type: EXPERIMENTAL
Intervention: Leg circulatory occlusion (occlusion)
Number of subjects: 48
Study: 24375428

Group type: EXPERIMENTAL
Intervention: Williams LifeSkills Training (WLST)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine intervention alone (control group)
Number of subjects: 66
Study: 22776810

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% (group LB)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lidocaine-adrenaline 1% with 1:200,000 (group LA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 90
Study: 19401905

Group type: EXPERIMENTAL
Intervention: Silk'n device (Home Pulsed Light)
Number of subjects: 34
Study: 17463418

Group type: EXPERIMENTAL
Intervention: Single oral dose of 2.5 mg vitamin D
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 14995984

Group type: EXPERIMENTAL
Intervention: DX‐9065a
Number of subjects: 175

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 175
Study: 11591229

Group type: EXPERIMENTAL
Intervention: Water-miscible retinyl palmitate (112 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Oil-soluble retinyl palmitate (112 mg)
Number of subjects: 9
Study: 9517717

Group type: EXPERIMENTAL
Intervention: Visible light-cured bonding material (Sequence)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chemically cured bonding material (System 1+)
Number of subjects: 32
Study: 11271260

Group type: EXPERIMENTAL
Intervention: Ganciclovir (DHPG) 3 mg/kg q 12 h for 2 weeks, plus CMV-hyperimmunglobulin (1 ml/kg per week for 6 weeks) if CMV+ donor
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (historical control, 18 patients, aged 53 ± 10 years)
Number of subjects: 20
Study: 3122967

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg in the morning
Number of subjects: 162

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 162
Study: 30602649

Group type: EXPERIMENTAL
Intervention: SNPs (DSNP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: ZNPs (DZNP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: TNPs (DTNP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No pretreatment (E)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No pretreatment (D)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SNPs (ESNP)
Number of subjects: 80
Study: 28110919

Group type: EXPERIMENTAL
Intervention: Topical anesthesia (Xylocaine gauze applied for 2 minutes)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (water gauze applied for 2 minutes)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Anxiety levels (measured by MDAS)
Number of subjects: 44
Study: 25673087

Group type: EXPERIMENTAL
Intervention: LB30870 60 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LB30870 120 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LB30870 (various doses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LB30870 (doses above 15 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: LB30870 (60 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LB30870 (up to 240 mg)
Number of subjects: 16
Study: 24284841

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20 mg triamcinolone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (40 mg and 20 mg)
Number of subjects: 100
Study: 21052021

Group type: EXPERIMENTAL
Intervention: CCB (amlodipine)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ARB (losartan)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both CCB and ARB
Number of subjects: 44
Study: 18444815

Group type: EXPERIMENTAL
Intervention: 2 g of metronidazole under directly observed therapy
Number of subjects: 361
Study: 16472979

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate (CHO) solution
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 6-g essential amino acid (EAA) mixture
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined CHO+EAA supplement
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 32
Study: 14512130

Group type: EXPERIMENTAL
Intervention: 2 loratadine 5‐mg tablets + ambroxol 30‐mg tablets (Formulation A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 loratadine 10‐mg tablet (Formulation C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 ambroxol 30‐mg tablets (Formulation B)
Number of subjects: 30
Study: 11251432

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 32
Study: 9506640

Group type: EXPERIMENTAL
Intervention: Hydrolysate formula (Alimentum)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional infant formula (Similac)
Number of subjects: 23
Study: 7924865

Group type: EXPERIMENTAL
Intervention: Preoperative parenteral nutritional support (PNS) for 5 days, yielding 117 Kj.kg‐1.d‐1 of non‐protein calories and 0.15g.kg‐1.d‐1 of nitrogen.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Chemotherapy with 5‐Fu at 8‐10mg.kg‐1.d‐1 for 5 days and mitomycin C at 6‐8mg.d‐1 on the first and fifth day.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PNS plus chemotherapy (5‐Fu and mitomycin C) as in Groups A and B.
Number of subjects: 19
Study: 3254831

Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 22
Study: 31524941

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (2.5 mg twice a day) plus Aspirin (100 mg once a day)
Number of subjects: 27395

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (5 mg twice a day)
Number of subjects: 27395

Group type: COMPARATOR
Intervention: Aspirin (100 mg once a day)
Number of subjects: 27395
Study: 30488637

Group type: EXPERIMENTAL
Intervention: Antipsychotic dose reduction strategy with evidence-based intensive recovery treatment (DRS+)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Antipsychotic maintenance treatment with evidence-based intensive recovery treatment (AMTx+)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Antipsychotic dose reduction strategy (DRS+)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Antipsychotic maintenance treatment (AMTx+)
Number of subjects: 180
Study: 28501729

Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract (36mg of active component-1-deoxynojirimycin)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (cornflakes with low fat milk)
Number of subjects: 25
Study: 26287882

Group type: EXPERIMENTAL
Intervention: Wavefront-guided PRK (Zyoptix)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Aspheric PRK (Technolas 217z)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both PRK methods
Number of subjects: 48
Study: 22967208

Group type: EXPERIMENTAL
Intervention: Alkalinized intravesical ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 40
Study: 22049410

Group type: EXPERIMENTAL
Intervention: Increased theta power and decreased beta power during memory encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stronger activity in the left inferior prefrontal cortex and right parahippocampal gyrus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta power in the left inferior prefrontal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theta power in medial temporal lobe regions
Number of subjects: 0
Study: 19421910

Group type: EXPERIMENTAL
Intervention: Bankart repair using Mitek GI/GII anchors combined with capsular imbrication (n = 33)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Putti‐Platt procedure (n = 33)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Stable shoulders (n = 28)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Unstable shoulders (n = 34)
Number of subjects: 66
Study: 16123771

Group type: EXPERIMENTAL
Intervention: Mecamylamine
Number of subjects: 15
Study: 15133709

Group type: EXPERIMENTAL
Intervention: Eyes with disc hemorrhages
Number of subjects: 78

Group type: COMPARATOR
Intervention: Eyes without disc hemorrhages
Number of subjects: 78
Study: 11511434

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 0
Study: 9147610

Group type: EXPERIMENTAL
Intervention: Idarubicin (Ida) 10 mg/m2 given as a 3 min infusion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Idarubicin (Ida) 10 mg/m2 given as a 2 h infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Idarubicin (Ida) in combination with Cytosine arabinoside (Ara‐C, 1 g/m2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Idarubicin (Ida)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Idarubicin (Ida) as prolonged infusion
Number of subjects: 17
Study: 8345007

Group type: EXPERIMENTAL
Intervention: Phenytoin Sodium
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Epanutin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Single 300-mg dose of phenytoin at 08.00 hours
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Single 300-mg dose of phenytoin at 20.00 hours
Number of subjects: 14
Study: 31119515

Group type: EXPERIMENTAL
Intervention: Spiritist 'passe' intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 0
Study: 31495592

Group type: EXPERIMENTAL
Intervention: PCV20
Number of subjects: 66

Group type: COMPARATOR
Intervention: Tdap (control)
Number of subjects: 66
Study: 28590768

Group type: EXPERIMENTAL
Intervention: Hydroalcoholic extract of Capsella bursa pastoris
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24911173

Group type: EXPERIMENTAL
Intervention: Group 1 (attention to somatic arousal)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Group 2 (distraction from somatic arousal)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Group 3 (no distractions or interoceptive prompts)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (stationary biking)
Number of subjects: 33
Study: 23471268

Group type: EXPERIMENTAL
Intervention: GSK249320 (1, 5, or 15 mg/kg per infusion)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 21724317

Group type: EXPERIMENTAL
Intervention: Mechanical chest compression device LUCAS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 21
Study: 18091023

Group type: EXPERIMENTAL
Intervention: rs17036314
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: rs1801282 (Pro12Ala)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Change in physical activity (PA)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: rs1152003
Number of subjects: 479
Study: 16855077

Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 14614791

Group type: EXPERIMENTAL
Intervention: Selective processing task (modified Stroop)
Number of subjects: 47
Study: 10752681

Group type: EXPERIMENTAL
Intervention: 5 years of adjuvant tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2 years of adjuvant tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged tamoxifen therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy
Number of subjects: 0
Study: 8855856

Group type: EXPERIMENTAL
Intervention: Oral ferrous sulphate (650 mg twice daily)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 1387604

Group type: EXPERIMENTAL
Intervention: Preservative-containing ipratropium bromide
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Preservative-free ipratropium bromide
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: pH 7 preservative-free ipratropium bromide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 50
Study: 6828092

Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg intravenously initially, then 200 mg daily for three months)
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Placebo (697 patients)
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study: 30565397

Group type: EXPERIMENTAL
Intervention: FIREHAWK sirolimus-eluting stent
Number of subjects: 1007
Study: 29678619

Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 27310103

Group type: EXPERIMENTAL
Intervention: Preservative-free latanoprost
Number of subjects: 30

Group type: COMPARATOR
Intervention: Preserved latanoprost
Number of subjects: 30
Study: 25695295

Group type: EXPERIMENTAL
Intervention: Inhaled colistin/oral ciprofloxacin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nebulized tobramycin 300 mg/oral ciprofloxacin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (chronically colonized patients)
Number of subjects: 40
Study: 22110163

Group type: EXPERIMENTAL
Intervention: AM211 200 mg once daily for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AM211 (various doses 100 to 600 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AM211 (multiple dosing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AM211 (all doses)
Number of subjects: 0
Study: 20889993

Group type: EXPERIMENTAL
Intervention: High-dose tirofiban (25 μg/kg) in addition to acetylsalicylic acid, unfractionated heparin, and 600 mg clopidogrel.
Number of subjects: 648

Group type: COMPARATOR
Intervention: Placebo in addition to acetylsalicylic acid, unfractionated heparin, and 600 mg clopidogrel.
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: High-dose tirofiban (25 μg/kg).
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: PFA-100 (both cartridges).
Number of subjects: 648
Study: 17846979

Group type: EXPERIMENTAL
Intervention: 30% calorie restricted diet over 12 weeks
Number of subjects: 25
Study: 15103594

Group type: COMPARATOR
Intervention: NIR stent
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: NIROYAL stent
Number of subjects: 603
Study: 11665396

Group type: EXPERIMENTAL
Intervention: 0.3% Flurbiprofen gel
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.3% Triclosan gel
Number of subjects: 16
Study: 9678314

Group type: EXPERIMENTAL
Intervention: APOE epsilon4/4 genotype
Number of subjects: 1131

Group type: EXPERIMENTAL
Intervention: APOE epsilon3/4 genotype
Number of subjects: 1131

Group type: EXPERIMENTAL
Intervention: APOE epsilon4 allele
Number of subjects: 1131

Group type: EXPERIMENTAL
Intervention: APOE genotypes
Number of subjects: 1131
Study: 7991885

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms via metered dose inhaler, twice daily for 2 weeks)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Theophylline (individually dose‐titrated, twice daily for 2 weeks)
Number of subjects: 141
Study: 2643845

Group type: EXPERIMENTAL
Intervention: Propranolol (120 to 160 mg daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Verapamil (320 mg daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29324576

Group type: EXPERIMENTAL
Intervention: Cooling vest (VG) during recovery periods within a training session (8 bouts of 5-minute fighting with 5-minute rest) and up to 10 minutes after the session
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cooling vest (VG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CG) without cooling aids
Number of subjects: 16
Study: 28595341

Group type: EXPERIMENTAL
Intervention: CPAP withdrawal
Number of subjects: 31
Study: 25686323

Group type: EXPERIMENTAL
Intervention: Ridge-preservation procedure with Bio‐Oss® and Bio‐Gide® (RP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Extraction alone (EXT)
Number of subjects: 16
Study: 23608924

Group type: EXPERIMENTAL
Intervention: Scripted debriefing
Number of subjects: 387

Group type: COMPARATOR
Intervention: Nonscripted debriefing
Number of subjects: 387
Study: 21736494

Group type: EXPERIMENTAL
Intervention: 3-month aerobic regular exercise (moderate-intensity power walking)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-exercise (sedentary)
Number of subjects: 60
Study: 20109380

Group type: EXPERIMENTAL
Intervention: Idrastin lymph‐draining cream with elastocompressive therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Elastocompressive therapy only
Number of subjects: 80
Study: 16677228

Group type: EXPERIMENTAL
Intervention: Northern sites
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Bipolar II patients
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Southern sites
Number of subjects: 1000
Study: 12727154

Group type: EXPERIMENTAL
Intervention: Preserved left ventricular systolic function
Number of subjects: 5491

Group type: EXPERIMENTAL
Intervention: Reduced left ventricular systolic function
Number of subjects: 5491

Group type: EXPERIMENTAL
Intervention: Younger patients with ischemic heart disease
Number of subjects: 5491

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 5491
Study: 10809036

Group type: EXPERIMENTAL
Intervention: Orlistat, 120 mg 3 times a day for 104 weeks
Number of subjects: 675

Group type: COMPARATOR
Intervention: Placebo 3 times a day for 104 weeks
Number of subjects: 675
Study: 8614396

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CT) with lomustine (CCNU), vincristine, and prednisone for 1 year
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cranio-spinal irradiation (CSI) alone
Number of subjects: 36
Study: 1600529

Group type: EXPERIMENTAL
Intervention: Propafenone at 300 mg twice daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hydroquinidine retard 250 mg twice daily
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hydroquinidine
Number of subjects: 200
Study: 3904258

Group type: EXPERIMENTAL
Intervention: 5 micrograms ml‐1 hepatitis B vaccine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 10 micrograms ml‐1 hepatitis B vaccine
Number of subjects: 98
Study: 29557709

Group type: EXPERIMENTAL
Intervention: Fasiglifam (TAK-875)
Number of subjects: 0
Study: 29958034

Group type: EXPERIMENTAL
Intervention: Multi-ingredient detoxification supplement (1,350 mg/serving)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 28662266

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study: 26432552

Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures (n = 179)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Conventional sutures (n = 178)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 357
Study: 23400916

Group type: EXPERIMENTAL
Intervention: 5-minute infusion of ertapenem 1 g
Number of subjects: 12

Group type: COMPARATOR
Intervention: 30-minute infusion of ertapenem 1 g
Number of subjects: 12
Study: 20091057

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 20